BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
NASA Artemis 2 astronauts to make historic moon flyby today. Here's what to expect hour by hour (timeline) - 2Nurturing Hacks: Shrewdness from Experienced Mothers and Fathers
- 3South African army arrive in crime hotspots to help tackle gangs
- 4Pick Your Favored kind of soup
- 56 Fun Urban areas For Seniors To Travel
- Explainer-What has happened to the damaged spacecraft at China's space station?
- Germany's far-right AfD tops poll ahead of Merz's conservatives
- Setbacks in Texas and elsewhere put Republicans' redistricting hopes in doubt as key deadlines loom
- At 72, Kathie Lee Gifford says aging isn’t what she expected. 'The golden years? It’s a lie.’
- Traveling Alone: An Excursion of Self-Disclosure
- 10 Moving Design Frill for Summer 2023
- Midlife weight gain can start long before menopause – but you can take steps early on to help your body weather the hormonal shift
- Tech Patterns: Contraptions That Will Shape What's in store
- More charges filed against ex-left-wing RAF member Daniela Klette
